INTRODUCTION AND OBJECTIVES: In recent years, medical expulsive therapy has been questioned in the management of distal ureteric stones. Therefore, we conducted a prospective randomized study to evaluate the possible role of tadalafil individually and in comparison with proven tamsulosin as well as a placebo therapy in distal ureteric stone expulsion.
METHODS: Between January 2015 and March 2016, 327 patients who presented with distal ureteric stones of size 5e10 mm were randomly divided into three groups: tadalafil (Group A), tamsulosin (Group B), and placebo (Group C). Therapy was given for a maximum of 4 weeks. Stone expulsion rate, time to stone expulsion, analgesic use, number of hospital visits for pain, follow-up, endoscopic treatment and adverse effects of drugs were noted.
RESULTS: A statistically significant expulsion rate of 86.0% in Group A compared with 66.0% in Group B and 38.0% in Group C was observed. Also a shorter stone expulsion time in Group A (13.5 AE 2.5) in comparison to Group B (16.4 AE 3.5) and Group C (24.8 AE 4.5) was observed. Statistically significant differences were noted in renal colic episodes and analgesic requirement in Group A in comparison to Group B and Group C. No serious adverse effects were noted. CONCLUSIONS: Tadalafil is safe, efficacious, and well tolerated as medical expulsive therapy for distal ureteric stones. This study showed that tadalafil increases ureteric stone expulsion quite significantly along with better control of pain and significantly lower analgesic requirement. 
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INTRODUCTION AND OBJECTIVES:
Animal and human studies have evaluated the role of low-intensity extracorporeal shockwave therapy (LIST) in the management of multiple disorders. LIST is thought to release angiogenic factors and recruit endothelial progenitor cells, inducing neovascularization. The aim of the study is to investigate the effects of penile LIST on erectile function in patients suffering erectile dysfunction (ED) refractory to phosphodiesterase type 5 inhibitors (PDE5i) METHODS: Prospective, randomized, simple-blind, shamcontrolled study. 58 patients with vasculogenic ED refractory to PDE5i were randomized into two groups. 30 were treated with electrohydraulic LIST (1 session/week for 6 weeks; 1,500 pulses of 0.10 mJ/mm2 at 5 Hz) and 28 were treated with a sham probe. 11 patients withdrew from the study and were lost to follow-up. Patients were evaluated at baseline and 1 month after the end of treatment using validated ED questionnaires. Fisher's exact or Student's t-test were used. Results were considered statistically significant at p<0.05 RESULTS: 27 active-treated patients and 20 sham-treated patients completed the one-month follow-up. There was no significant difference between the two groups in baseline characteristics. Baseline five-item version of the International Index of Erectile Function (IIEF-5) mean scores, in the active and sham groups, were 10.0 AE 3.9 and 10.0 AE 4.5, respectively (p¼ 0.863). At baseline, 48.1% of patients in the active group and 50.0% of patients in the placebo group had a positive answer to the Sexual Encounter Profile (SEP) 2 question (p¼1.000); 11.1% of patients in the active group and 10.0% of patients in the placebo group had a positive answer to the SEP 3 question (p¼1.000). One month after treatment IIEF-5 scores mean changes from baseline, in the active and placebo group, were 1.6 AE 4.7 and 0.5 AE 4.4, respectively (p¼0.478). SEP 3 positive responders increased by 18.5% in the active group and by 0% in the placebo group ( METHODS: Systematic search of MEDLINE, EMBASE, and ClinicalTrials.gov for randomized controlled trials that had been published in peer-reviewed journals or presented in abstract form of Li-ESWT used for the treatment of erectile dysfunction between January 2010 and March 2016. Randomized controlled trials were eligible for inclusion if they were published in the peer-reviewed literature and assessed erectile function outcomes using the IIEF-EF. Estimates were pooled using random-effects meta-analysis. The main outcome measure was the change in IIEF-EF after treatment with Li-ESWT in patients treated with active treatment and sham LiESWT probes.
RESULTS: Data were extracted from 7 trials involving 602 participants. The average age was 60.7 years and the average followup was 19.8 weeks. There was a statistically significant improvement in pooled change in IIEF-EF from baseline to follow-up in men undergoing Li-ESWT compared to those undergoing sham therapy (6.40 points [95% CI: 1.78 to 11.02; I2 ¼ 98.7%, P < 0.0001] vs. 1.65 points [95% CI: 0.92 to 2.39; I2 ¼ 64.6%, P < 0.0001]; between-group difference, P ¼ 0.047). Significant between-group differences were found for total treatment shocks received by patients (P < 0.0001).
CONCLUSIONS: In this meta-analysis of seven randomized controlled trials, treatment of ED with Li-ESWT resulted in a significant increase in IIEF-EF scores. METHODS: Eighty seven sexually active men with muscle invasive bladder cancer were enrolled in this prospective study. After bilateral NS-RCP with orthotopic diversion (W-Pouch) by a single expert surgeon between January 2015 & October 2016, patients were randomized into 3 groups (29 patients/group). SWL Group received 12 sessions of penile LI-SWT (2/week for 3 weeks, then 3 weeks free of treatment, then 2/week for another 3 weeks). Phosphodiesterase type-5 inhibitors (PDE5i) Group received oral PDE5i of 50 mg /day for 6 months. Control Group was followed up only without any therapy. Patients were assessed before surgery and at 1 (FU1), 3 (FU2), 6 (FU3) and 9-month (FU4) post operatively. Effectiveness was assessed by IIEF-15 questionnaire and erection hardness score (EHS).
RESULTS: Mean age was 54.1 AE 5.9 years with mean followup period 15.9 AE 4.2 months. There were no statistically significant differences regarding preoperative patients demographic data & tumor criteria. At FU1; All patients have insufficient erection for vaginal penetration. EHS < 2; with decrease of preoperative IIEF-EF mean score from 28 to 6.6. In SWL group; At FU2; 17/29 patients regained potency which is maintained in 15 only at FU3&4. However; 6 of remaining 12 patients regained & maintained potency at FU3&4. Statistical evaluation showed significant increase in IIEF-EF score from 6.6 at FU1 to 23 at FU2, 24 at FU3 and 24.5 at FU4 ( P <0.001). In PDE5i group; At FU2; 16/29 patients regained & maintained potency at FU3&4. However; 7 of remaining 13 patients regained & maintained potency at FU3&4. Statistical evaluation showed significant increase in IIEF-EF score from 6.6 at FU1 to 22.8 at FU2, 24 at FU3 and 24.7 at FU4 (P <0.001). In Control group; At FU2; 12/29 patients regained & maintained potency at FU3&4. However; 6 of remaining 17 patients regained & maintained potency at FU3&4. Statistical evaluation showed no significant difference in potency recovery rates at FU2 & FU3,4 among the groups ( P ¼ 0.14 & P ¼ 0.24 respectively). Potency recovery rates at FU2 were 58.6% vs 55.2% vs 41.4% in SWL, PDE5i and Control group, respectively. While potency recovery rates at FU3,4 were 72.4% vs 79.3% vs 62.1% in SWL, PDE5i and Control group, respectively. CONCLUSIONS: LI-SWT is safe and as effective as oral PDE5i in PR post NS-RCP. A large-scale study is required to determine the value of this treatment modality in ED post NS-RCP.
Source of Funding: None
MP91-04 ADVERSE EFFECTS OF TESTOSTERONE REPLACEMENT THERAPY FOR MEN, A MATCHED COHORT STUDY
INTRODUCTION AND OBJECTIVES: Determine the association of Testosterone Replacement Therapy (TRT) with event free survival and absolute risk of hepatotoxicity, thromboembolic cardiovascular events, and obstructive sleep apnea (OSA) in a cohort of healthy adult men using TRT.
METHODS: We queried the TRICARE military database, which comprises all retired and active duty men and women and their immediate family members, who receive insurance through the military. Men age 18-65, diagnosed with hypogonadism who received TRT between 2006-2010 were included. We compared event-free survival and absolute risk of hepatotoxicity, thromboembolic and cardiovascular events, and obstructive sleep apnea (OSA) between men using TRT and controls.
RESULTS: Relative to controls, patients using TRT had improved cardiovascular event free survival (p¼0.004). There was no significant difference in event free survival for hepatotoxicity (p¼0.345), and thromboembolic events (p¼0.239). Absolute two-year risk for men using TRT was 0.02 for hepatotoxicity, 0.06 for Cardiac events, 0.02 for thromboembolic events and 0.17 for Sleep Apnea. Absolute 2-year risk was similar with the exception with OSA, which had higher 2-year absolute risk (95% CI: 1.56%-1.84% of TRT users vs. 1.1%-1.4% in controls).
CONCLUSIONS: In our cohort of there was no significant increase in risk of hepatotoxicity, and thromboembolic complications among men using TRT. Additionally, men using TRT had modestly prolonged cardiovascularevent-free survival. Prior studies suggesting elevated risk of cardiovascular effects may be less generalizable to healthy young men using TRT in a community setting. . 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1219
